[HTML][HTML] HPV vaccines–a review of the first decade
DM Harper, LR DeMars - Gynecologic oncology, 2017 - Elsevier
Abstract Pre-adolescent girls (9–15 years) have the option of receiving a two dose HPV
vaccine series at either a six month or one year interval to provide protection from HPV 16 …
vaccine series at either a six month or one year interval to provide protection from HPV 16 …
Effect of vaccine administration modality on immunogenicity and efficacy
L Zhang, W Wang, S Wang - Expert review of vaccines, 2015 - Taylor & Francis
The many factors impacting the efficacy of a vaccine can be broadly divided into three
categories: features of the vaccine itself, including immunogen design, vaccine type …
categories: features of the vaccine itself, including immunogen design, vaccine type …
Instructing durable humoral immunity for COVID-19 and other vaccinable diseases
D Bhattacharya - Immunity, 2022 - cell.com
Many aspects of SARS-CoV-2 have fully conformed with the principles established by
decades of viral immunology research, ultimately leading to the crowning achievement of …
decades of viral immunology research, ultimately leading to the crowning achievement of …
Safety of human papillomavirus vaccines: an updated review
A Phillips, C Patel, A Pillsbury, J Brotherton… - Drug safety, 2018 - Springer
Human papillomavirus (HPV) vaccines are now included in immunisation programmes in 71
countries. Unfortunately, uptake has been impacted in some countries by reduced …
countries. Unfortunately, uptake has been impacted in some countries by reduced …
Role of multivalency and antigenic threshold in generating protective antibody responses
MK Slifka, IJ Amanna - Frontiers in immunology, 2019 - frontiersin.org
Vaccines play a vital role in protecting our communities against infectious disease.
Unfortunately, some vaccines provide only partial protection or in some cases vaccine …
Unfortunately, some vaccines provide only partial protection or in some cases vaccine …
Recombinant human papillomavirus nonavalent vaccine in the prevention of cancers caused by human papillomavirus
ZQ Toh, J Kosasih, FM Russell… - Infection and drug …, 2019 - Taylor & Francis
Human papillomavirus (HPV) types 16 and 18 cause 70% of cervical cancer cases globally.
The nonavalent HPV vaccine (9vHPV) was licensed in 2014 and protects against the next …
The nonavalent HPV vaccine (9vHPV) was licensed in 2014 and protects against the next …
[HTML][HTML] Immunogenicity of HPV prophylactic vaccines: serology assays and their use in HPV vaccine evaluation and development
LA Pinto, J Dillner, S Beddows, ER Unger - Vaccine, 2018 - Elsevier
When administered as standard three-dose schedules, the licensed HPV prophylactic
vaccines have demonstrated extraordinary immunogenicity and efficacy. We summarize the …
vaccines have demonstrated extraordinary immunogenicity and efficacy. We summarize the …
Developments in L2-based human papillomavirus (HPV) vaccines
C Schellenbacher, RBS Roden, R Kirnbauer - Virus research, 2017 - Elsevier
Infections with sexually transmitted high-risk Human Papillomavirus (hrHPV), of which there
are at least 15 genotypes, are responsible for a tremendous disease burden by causing …
are at least 15 genotypes, are responsible for a tremendous disease burden by causing …
Differences in HPV-specific antibody Fc-effector functions following Gardasil® and Cervarix® vaccination
Abstract Gardasil®(Merck) and Cervarix®(GlaxoSmithKline) both provide protection against
infection with Human Papillomavirus 16 (HPV16) and Human Papillomavirus 18 (HPV18) …
infection with Human Papillomavirus 16 (HPV16) and Human Papillomavirus 18 (HPV18) …
[HTML][HTML] HPV vaccination in HIV infection
CJN Lacey - Papillomavirus research, 2019 - Elsevier
Persons with HIV are at increased risk of HPV infection, HPV disease, and HPV-related
cancers compared to HIV negative persons. In persons with HIV, immune responses to …
cancers compared to HIV negative persons. In persons with HIV, immune responses to …